SOM Biotech wants to act as catalyst to translate orphan disease research into the development of new effective and safe medicines.
Founded in 2009, SOM has developed all through the years a unique business model based on the know-how and expertise of talented people, always driven by curiosity, excellence and an instinct of self-improvement.
We use Artificial Intelligence to bring therapeutic solutions to the patients without a time-consuming and ineffective R&D process.
The SOM Biotech team is made up of 11 talented people with experience in the discovery and development of medicines, always driven by curiosity, excellence and a personal development instinct.
The pipeline of SOM Biotech mainly contains programs focused on Orphan indications.
All programs are obtained through the proprietary AI-based technology.
1. SOM3355
SOM3355 is an oral VMAT2 inhibitor (vesicular monoamine transporter 2) for the symptomatic treatment of chorea movements associated with Huntington’s disease (HD), and other hyperkinetic movement disorders. SOM3355 is currently in Phase 2a trials in HD and has shown a favorable safety profile with no depression effects. You can find more information about Clinical trials for SOM3355 here NCT03575676.
Huntington’s disease is an inherited disease that causes the progressive breakdown (degeneration) of nerve cells in the brain. Huntington’s disease has a broad impact on a person’s functional abilities and usually results in movement, thinking (cognitive) and psychiatric disorders.
2. SOM1311
SOM1311 is a small molecule pharmacological chaperone of Phenylalanine Hydroxylase for the treatment of Phenylketonuria.
Phenylketonuria (PKU) is is characterized by an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated, PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorders.
3. SOM0208
SOM0208 is a small molecule for the treatment of Niemann–Pick C disease.
Niemann–Pick type C is a lysosomal storage disorder caused by defects in the intracellular transport and metabolism of cholesterol and glycolipids. The disease has a broad clinical spectrum. Affected individuals may have enlargement of the spleen (splenomegaly) and liver (hepatomegaly), or enlarged spleen or liver combined (hepatosplenomegaly), but this finding may be absent in later onset cases. Prolonged jaundice or elevated bilirubin can present at birth.
Reduction of the price (in 20-4k times) and the duration (in 2-5 times) of the development of medications and faster delivery of medications to patients with unmet medical needs.
Pharmaceutical Companies and Research Centers
La Vanguardia published a press release: 'The future of biotechnology: lower-cost treatments in a short period of time'
Som Biotech
European Biotechnology: 'A pioneering real AI drug discovery technology'
Som Biotech
SOM Biotech keynote speaker at the Drug Discovery Innovation Programme Virtual Event 2020
Som Biotech
SOM Biotech presents its drug candidate for the Chorea in Huntington Disease at the XIX Pharma – Biotech Cooperation conference
Som Biotech
SOM Biotech announces poster presentation on the repurposing of Eravacycline for the treatment of SARS-CoV-2
Som Biotech
SOM Biotech has attended the virtual workshop on the World Duchenne Awareness Day 2020
Som Biotech
SOM Biotech is awarded a grant from CDTI to start clinical trials with a drug inhibitor of SARS- COV-2 replication
Som Biotech
SOM Biotech appoints Alain Duguet PhD as Head of Chemical Manufacturing and Control
Som Biotech
SOM Biotech attended the BIO International Convention 2020
Som Biotech
SOM Biotech keynote speaker at the Euronext webinar
Som Biotech
